Effect of CPAP on Blood Pressure in Patients With Sleep Apnea and Refractory Hypertension

Effect of Continuous Positive Airway Pressure (CPAP) Treatment on Blood Pressure in Patients With Sleep Apnea and Refractory Hypertension

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00863135

Enrollment

Registered

2009-03-17

Start date

2008-12-31

Completion date

2016-07-31

Last updated

2017-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea, Refractory Arterial Hypertension

Keywords

obstructive sleep apnea, refractory arterial hypertension, continuous positive airways pressure

Brief summary

The purpose of this study is to determine the effects of CPAP treatment on blood pressure in patients with sleep apnea syndrome (SAS) and refractory arterial hypertension (RAH). Also, some of the mechanisms mediating SAS and RAH (systemic inflammation, oxidative stress, sympathetic hyperactivity) will be analyzed.

Interventions

DEVICECPAP

continuous positive airways pressure

DEVICEControl

Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* refractory arterial hypertension and sleep apnea with apnea-hypopnea index over 15

Exclusion criteria

* excessive sleepiness * professional drivers * secondary arterial hypertension

Design outcomes

Primary

Measure	Time frame
24 hours blood pressure monitoring	basal and after three months of CPAP treatment

Secondary

Measure	Time frame
oxidative stress and inflammatory mediators	basal and after three months of CPAP treatment

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026